Hofseth BioCare ASA (OSL:HBC)

Inozyme Pharma Ratios and Metrics

Market cap in millions NOK. Fiscal year is January - December.

Fiscal Year	Current	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Aug 1, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Market Capitalization	732	699	1,035	1,300	2,469	3,507
Market Cap Growth	23.06%	-32.49%	-20.36%	-47.36%	-29.59%	19.59%
Enterprise Value	895	870	1,116	1,359	2,523	3,625
Last Close Price	1.78	1.70	2.62	3.29	6.90	9.80
Forward PE	-	1.52	1.52	1.52	1.52	1.52
PS Ratio	2.67	2.63	4.74	10.79	28.18	50.64
PB Ratio	27.88	11.77	25.16	8.78	17.59	13.30
P/TBV Ratio	32.40	12.47	28.44	9.14	28.06	13.44
P/OCF Ratio	-	-	374.91	-	-	-
EV/Sales Ratio	3.27	3.28	5.11	11.29	28.80	52.34
Debt / Equity Ratio	9.00	2.88	6.83	0.70	0.99	0.38
Asset Turnover	0.71	0.73	0.55	0.29	0.20	0.18
Inventory Turnover	2.89	2.74	1.66	0.99	0.94	0.74
Quick Ratio	0.50	0.30	0.17	0.31	0.49	1.83
Current Ratio	0.84	0.67	0.52	1.02	1.13	2.56
Return on Equity (ROE)	-142.28%	-249.37%	-112.79%	-95.28%	-62.58%	-53.52%
Return on Assets (ROA)	-17.03%	-18.00%	-16.00%	-19.41%	-16.94%	-15.29%
Return on Capital (ROIC)	-22.68%	-23.79%	-22.32%	-30.19%	-23.01%	-18.71%
Earnings Yield	-17.69%	-17.93%	-10.31%	-10.57%	-5.12%	-2.91%
FCF Yield	-0.89%	-1.75%	-0.53%	-3.78%	-3.43%	-2.69%
Buyback Yield / Dilution	-3.05%	-4.01%	-5.43%	-4.72%	-7.25%	-8.96%

Updated Feb 14, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.